



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

13 February 2026  
EMADOC-1700519818-2885543  
Committee for Veterinary Medicinal Products (CVMP)

## Summary of opinion<sup>1</sup> (post-authorisation)

---

### Suvaxyn PRRS MLV

Vaccine common name: Porcine respiratory and reproductive syndrome virus vaccine (live)

On 12 February 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion<sup>2</sup>, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Suvaxyn PRRS MLV. The marketing authorisation holder for this veterinary medicinal product is Zoetis Belgium.

Suvaxyn PRRS MLV is currently authorised for administration via the intramuscular or intranasal route. This variation concerns the addition of an option to administer Suvaxyn PRRS MLV (0.5-ml dose only) to pigs for fattening intramuscularly using a needle-free device.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

---

<sup>1</sup> Summaries of opinion are published without prejudice to the Commission Decision.

<sup>2</sup> Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

